NCT02979977 2026-02-04
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Yale University
Phase 2 Completed
Clinical Trials
23 trialsNCT01856478 2026-01-12
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT06494189 2025-12-29
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
West China Hospital
Phase 1 Completed
NCT06804850 2025-11-19
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
West China Hospital
Phase 2 Withdrawn
NCT06897735 2025-11-18
EDDIS-a1
Petrov, Andrey
Phase 1 Not yet recruiting
NCT05517330 2025-07-31
neoCHANCE-1
West China Hospital
Phase 2 Completed
NCT07010120 2025-06-13
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
West China Hospital
Phase 1/2 Recruiting
NCT05516589 2025-05-22
neoCHANCE-2
West China Hospital
Phase 2 Completed
NCT01783587 2025-05-01
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT06741982 2024-12-19
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
West China Hospital
Phase 1 Recruiting
NCT06648096 2024-11-20
AFAN
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Phase 1/2 Recruiting
NCT03088059 2023-11-03
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Unknown
NCT01824823 2023-06-28
Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT03695510 2022-04-21
ALPHA
National Taiwan University Hospital
Phase 2 Completed
NCT01415674 2022-02-02
PREDICTOR
UNICANCER
Phase 2 Completed
NCT01427478 2021-06-01
BIBW2992ORL
Centre Leon Berard
Phase 3 Completed
NCT01732640 2018-07-26
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Terminated
NCT01538381 2018-07-09
Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01345682 2018-02-15
LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT01345669 2017-12-07
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Boehringer Ingelheim
Phase 3 Terminated
NCT02216617 2017-10-27
TAPIS
Groupe Oncologie Radiotherapie Tete et Cou
Phase 1 Completed
NCT01721525 2017-10-25
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00514943 2016-07-26
BIBW 2992 (Afatinib) in Head & Neck Cancer
Boehringer Ingelheim
Phase 2 Completed